Primary malignant mucosal melanoma of the maxillofacial area
Journal of the Korean Association of Oral and Maxillofacial Surgeons / Journal of the Korean Association of Oral and Maxillofacial Surgeons, (P)2234-7550; (E)2234-5930
2021, v.47 no.2, pp.76-81
https://doi.org/10.5125/jkaoms.2021.47.2.76
Hyounmin Kim (Department of Oral and Maxillofacial Surgery, Yonsei University College of Dentistry, Seoul)
Sanghoon Lee (Oral Oncology Clinic, Research Institute and Hospital, National Cancer Center, Goyang)
In-Ho Cha (Department of Oral and Maxillofacial Surgery, Yonsei University College of Dentistry, Seoul)
Hyung Jun Kim (Department of Oral and Maxillofacial Surgery, Yonsei University College of Dentistry, Seoul)
Woong Nam (Department of Oral and Maxillofacial Surgery, Yonsei University College of Dentistry, Seoul)
Hyounmin,
K.
, Sanghoon,
L.
, In-Ho,
C.
, Hyung,
J.
K.
, &
Woong,
N.
(2021). Primary malignant mucosal melanoma of the maxillofacial area. Journal of the Korean Association of Oral and Maxillofacial Surgeons, 47(2), 76-81, https://doi.org/10.5125/jkaoms.2021.47.2.76
Abstract
Objectives: We aimed to collect and report data from all patients who have been diagnosed with mucosal malignant melanoma to obtain the epidemiology and principles of current treatments.
Materials and Methods: Between January 2008 and December 2018, 20 patients underwent surgery or follow-up observations at Yonsei University Dental Hospital. The patients’ clinical information was reviewed retrospectively.
Results: Seventeen of 20 patients had undergone definitive surgery, while only 6 patients received adjuvant radiotherapy or systemic therapy. Eight of 20 patients, including those that had recurrent lesions, were provided immunotherapy. The 3-year survival for all stages was 50%, with a local recurrence rate of 75% and a metastasis rate of 65%.
Conclusion: The overall survival of patients receiving surgical treatment was longer than that of patients who did not undergo surgical resection.
Eight of 20 patients received immunotherapy as the first-line regimen at our clinic, and those patients exhibited longer overall survival compared to patients in reported keynote studies.
- keywords
-
Malignant melanoma,
Immunotherapy,
Oral cancer